eMedicine Specialties > Pediatrics: General Medicine > Nephrology

Hemorrhagic Fever With Renal Failure Syndrome

Author: Rajendra Bhimma, MB, ChB, Associate Professor of Pediatrics, Principal Specialist, Department of Pediatrics and Child Health, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, South Africa
Coauthor(s): Vellore K Sairam, MBBS, Assistant Professor, Department of Nephrology, Sri Ramachandra Medical College and Research Institute, India; Luther Travis, MD, William W Glauser Professor of Pediatrics and Pediatric Nephrology, Department of Pediatrics, Divisions of Nephrology and Diabetes, University of Texas Medical Branch and Children's Hospital
Contributor Information and Disclosures

Updated: May 14, 2008

Introduction

Background

Hemorrhagic fever with renal failure syndrome (HFRS) occurs mainly in Europe and Asia and is characterized by fever and renal failure associated with hemorrhagic manifestations. HFRS is caused by an airborne contact with secretions from rodent hosts infected with the group of viruses belonging to the genus Hantavirus of the family Bunyaviridae. In Europe, HFRS is caused by 3 hantaviruses: Puumala virus (PUUV), carried by the bank vole (Myodes glareolus); Dobrava virus (DOBV), carried by the mouse (Apodemus flavicollis); and Saaremaa virus (SAAV), carried by the striped field mouse (Apodemus agrarius). 

HFRS was initially recognized between 1913 and 1930 by Soviet scientists, who described sporadic outbreaks of fever with renal failure in the eastern Soviet Union. The disease came to the attention of the Western world in 1950, when the North American soldiers serving with the United Nations forces in Korea developed a febrile illness associated with shock, hemorrhage, and renal failure.

In 1993, in the southwestern United States, an outbreak of respiratory illness caused by the Sin Nombre virus, which belongs to the genus Hantavirus, occurred and was described as the Hantavirus pulmonary syndrome (HPS).

Pathophysiology

The pathogenesis is largely unknown, but findings from several studies have suggested that immune mechanisms play an important role. After the infection, marked cytokine production, kallikrein-kinin activation, complement pathway activation, or increased levels of circulating immune complexes occur. These components play an important role during the febrile and hypotensive stages. Damage to the vascular endothelium, capillary dilatation, and leakage are clinically significant features of the disease.

Antibody specific to the viral antigen can be detected close to the onset of HFRS symptoms. A vigorous response is often a marker of severe disease. T-cell activation occurs very early in the course of HFRS and is associated with an absolute increase in the number of neutrophils, monocytes, B cells, and CD8+ (suppressor) T cells. The number of helper (CD4+) T cells does not increase, resulting in a decrease in the ratio of helper-to-suppressor T cells. Virus has been cultured from B cells and monocytes but not from T cells. Therefore, T-cell activation is a response to infection of other cell types rather than a consequence of direct viral infection.

A possible role for immune complexes has also been suggested following the demonstration of immune complexes in serum, on the surface of red cells and platelets, in glomeruli, in renal tubules, and in urine. Activation of both classic and alternative complement pathways also occurs in HFRS. By activating complement and by triggering mediator release from platelets and inflammatory cells, immune complexes can produce the vascular injury that is the hallmark of the disease.

Some investigators have suggested that HFRS is primarily an allergic disease. This is based on the finding of early appearance of specific immunoglobulin E (IgE), the presence of IgE immune complexes, and the beneficial effects of therapy aimed at inhibiting allergic pathways.

Frequency

United States

The rodent reservoir of Seoul virus (Rattus norvegicus) are present in many port cities of the eastern United States and were introduced from Europe by cargo ships. Observations from enhanced surveillance for Hantavirus infection in humans eventually suggested the presence of HFRS caused by the pathogen in the Seoul infections in few reported cases.

International

The severe form of HFRS occurs in China, Japan, and Singapore. The number of cases reported in China is approximately 100,000-250,000 per year. The mild form of HFRS (nephropathic epidemica) occurs in the Scandinavian countries of Sweden, Finland, Norway, and Denmark.1 The disease is observed throughout the year, but the prevalence depends on the population dynamics of the carrier rodents.

Mortality/Morbidity

Mortality and morbidity rates vary from 5-15%, depending on the strain of the virus.

Race

No apparent racial predilection is known.

Sex

The increased incidence in male individuals is caused by their probable increased frequency of outdoor activities, which leads to contact with infected rodents.

Age

HFRS is commonly reported in persons older than 15 years. In children and adolescents younger than 15 years, the disease is mild and often subclinical.

Clinical

History

The clinical features consist of a triad of fever, hemorrhage, and renal insufficiency. Other common symptoms during the initial phase of the illness include headache, myalgia, abdominal and back pain, nausea, vomiting, and diarrhea. The disease may range from mild to severe. Subclinical infections are especially common in children. The average incubation period varies from 4-42 days. The disease is characterized by fever, hemorrhagic manifestations, and (if severe) hypovolemic shock.

The disease has 5 progressive stages: febrile, hypotensive, oliguric, diuretic, and convalescent.2 Physicians should be aware of the various presentations during each stage. Individual patients can completely skip stages.

Physical

Physical examination of the patient is based on the stage of the illness.

  • The febrile stage occurs in all patients and lasts about 4-6 days. The disease is characterized by an abrupt onset of fever with a temperature in the range of 40°C.
    • Patients may complain of headache, chills, abdominal pain, and malaise.
    • Flushing of the face, neck, and chest due to probable vascular dysregulation may be observed.
    • Petechia may occur in the axilla and soft palate.
    • Subconjunctival hemorrhage is noted in one third of patients.
    • Absolute bradycardia may be noted.
    • A normal or mildly elevated hematocrit level caused by hemoconcentration may be observed. Leucocytosis with atypical lymphocytes. The disease is characterized by thrombocytopenia, which also defines prognosis and severity of renal failure.
    • The onset of proteinuria and microhematuria can be observed. Proteinuria due to Hantavirus nephritis is transient and usually resolves within 2 weeks.
  • The hypotensive stage lasts approximately a few hours to 2 days. It occurs in 11% of patients and coincides with defervescence.
    • Patients may have tachycardia, which may indicate impending shock.
    • Patients may have acute abdomen caused by a paralytic ileus.
    • Patients may have convulsions or purposeless movements.
    • The coagulation profile may reveal a prolonged bleeding time, prothrombin time (PT), and activated partial thromboplastin time (aPTT).
  • The oliguric stage occurs in 65% of the patients and lasts about 3-6 days.
    • Oliguria, hypertension, bleeding tendency (caused by uremia), and edema are characteristic of this stage.
    • Patients may develop pulmonary edema.
    • Thrombocytopenia usually resolves in the oliguric stage.
  • The diuretic stage lasts 2-3 weeks.
    • Diuresis in the range of 3-6 L/d occurs after symptoms from the previous stage disappear. Responsiveness of the collecting duct to vasopressin is reduced.
    • Rapid signs of dehydration and severe shock can occur during this stage if fluid replacement is inadequate. The patient's volume status should be closely monitored.
  • The convalescent stage may last for as long as 3-6 months.
    • Clinical recovery usually begins in the middle of the second week, with a gradual resolution of symptoms and azotemia.
    • The concentrating capacity of the renal tubules recovers over many months.

Causes

The viruses of the genus Hantavirus cause different forms of hemorrhagic fever with renal failure syndrome (HFRS). The severity of the illness depends on the infecting virus and on the geographic distribution.

  • Korean hemorrhagic fever, a severe type of HFRS observed in Asia, is caused by a Hantavirus and is transmitted by the infected A agrarius mouse (striped field mouse).3
  • Balkan hemorrhagic fever, a severe type of HFRS observed in Balkan countries, is caused by the Dobrava virus and is transmitted by the infected A flavicollis mouse (yellow-necked field mouse).
  • A mild-to-moderate form of HFRS is caused by the Seoul virus and is transmitted by the infected Rattus rattus rat (black rat) or the Rattus novergicus rat (urban rat).
  • Nephropathia epidemica, a mild form of HFRS observed in Europe, is caused by the Puumala virus and is transmitted by the infected Clethrionomys glariolus vole (European bank vole).

More on Hemorrhagic Fever With Renal Failure Syndrome

Overview: Hemorrhagic Fever With Renal Failure Syndrome
Differential Diagnoses & Workup: Hemorrhagic Fever With Renal Failure Syndrome
Treatment & Medication: Hemorrhagic Fever With Renal Failure Syndrome
Follow-up: Hemorrhagic Fever With Renal Failure Syndrome
References

References

  1. Ahlm C, Settergren B, Gothefors L, Juto P. Nephropathia epidemica (hemorrhagic fever with renal syndrome) in children: clinical characteristics. Pediatr Infect Dis J. Jan 1994;13(1):45-9. [Medline].

  2. Ko KW. Haemorrhagic fever with renal syndrome: clinical aspects. Pediatr Nephrol. Mar 1992;6(2):197-200. [Medline].

  3. Bruno P, Hassell LH, Brown J, et al. The protean manifestations of hemorrhagic fever with renal syndrome. A retrospective review of 26 cases from Korea. Ann Intern Med. Sep 1 1990;113(5):385-91. [Medline].

  4. Huggins JW, Hsiang CM, Cosgriff TM, et al. Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. J Infect Dis. Dec 1991;164(6):1119-27. [Medline].

  5. Al-Hazmi M, Ayoola EA, Abdurahman M, et al. Epidemic Rift Valley fever in Saudi Arabia: a clinical study of severe illness in humans. Clin Infect Dis. Feb 1 2003;36(3):245-52. [Medline].

  6. Boonpucknavig V, Soontornniyomkij V. Pathology of renal diseases in the tropics. Semin Nephrol. Jan 2003;23(1):88-106. [Medline].

  7. Doyle TJ, Bryan RT, Peters CJ. Viral hemorrhagic fevers and hantavirus infections in the Americas. Infect Dis Clin North Am. Mar 1998;12(1):95-110. [Medline].

  8. Eboriadou M, Kalevrosoglou I, Varlamis G, et al. Hantavirus nephropathy in a child. Nephrol Dial Transplant. Apr 1999;14(4):1040-1. [Medline].

  9. Elisaf M, Korakis H, Siamopoulos KC. Chronic renal dysfunction in hemorrhagic fever with renal syndrome patients. Ren Fail. 1993;15(5):623-7. [Medline].

  10. Elisaf MS, Siamopoulos KC. Hemorrhagic fever with renal syndrome induced chronic renal dysfunction. Am J Nephrol. 1999;19(6):709. [Medline].

  11. Glass GE, Watson AJ, LeDuc JW, et al. Infection with a ratborne hantavirus in US residents is consistently associated with hypertensive renal disease. J Infect Dis. Mar 1993;167(3):614-20. [Medline].

  12. Golovljova I, Vasilenko V, Mittzenkov V, et al. Characterization of hemorrhagic fever with renal syndrome caused by hantaviruses, Estonia. Emerg Infect Dis. Nov 2007;13(11):1773-6. [Medline].

  13. Kim YK, Lee SC, Kim C, Heo ST, Choi C, Kim JM. Clinical and laboratory predictors of oliguric renal failure in haemorrhagic fever with renal syndrome caused by Hantaan virus. J Infect. Apr 2007;54(4):381-6. [Medline].

  14. Ko KW. Clinical quiz. Haemorrhagic fever with renal syndrome (HFRS, Korean haemorrhagic fever). Pediatr Nephrol. Oct 1995;9(5):537-8. [Medline].

  15. Lautala P, Uhari M. Epidemic nephropathy in children. Am J Dis Child. Oct 1991;145(10):1181-3. [Medline].

  16. Magill AJ. Fever in the returned traveler. Infect Dis Clin North Am. Jun 1998;12(2):445-69. [Medline].

  17. Makela S, Ala-Houhala I, Mustonen J, et al. Renal function and blood pressure five years after puumala virus-induced nephropathy. Kidney Int. Oct 2000;58(4):1711-8. [Medline].

  18. Mustonen J, Vaheri A, Clement J. Third International Conference on Haemorrhagic Fever with Renal Syndrome (HFRS) and Hantaviruses. Nephrol Dial Transplant. Apr 1996;11(4):730-3. [Medline].

  19. Niklasson BS. Haemorrhagic fever with renal syndrome, virological and epidemiological aspects. Pediatr Nephrol. Mar 1992;6(2):201-4. [Medline].

  20. Papadimitriou M. Hantavirus nephropathy. Kidney Int. Sep 1995;48(3):887-902. [Medline].

  21. Papadimitriou MG, Antoniadis A. Hantavirus nephropathy in Greece. Lancet. Apr 23 1994;343(8904):1038. [Medline].

  22. Peco-Antic A, Popovic-Rolovic M, Gligic A, et al. Clinical characteristics of haemorrhagic fever with renal syndrome in children. Pediatr Nephrol. Jul 1992;6(4):335-8. [Medline].

  23. Peters CJ, Simpson GL, Levy H. Spectrum of hantavirus infection: hemorrhagic fever with renal syndrome and hantavirus pulmonary syndrome. Annu Rev Med. 1999;50:531-45. [Medline].

  24. Rasche FM, Uhel B, Kruger DH, et al. Thrombocytopenia and acute renal failure in Puumala hantavirus infections. Emerg Infect Dis. Aug 2004;10(8):1420-5. [Medline].

  25. Yoo KH, Choi Y. Haemorrhagic fever with renal syndrome in Korean children. Korean Society of Pediatric Nephrology. Pediatr Nephrol. Oct 1994;8(5):540-4. [Medline].

  26. Zeier M, Handermann M, Bahr U, et al. New ecological aspects of hantavirus infection: a change of a paradigm anda challenge of prevention--a review. Virus Genes. Mar 2005;30(2):157-80. [Medline].

Further Reading

Keywords

hemorrhagic fever with renal failure syndrome, HFRS, epidemic hemorrhagic fever, Korean hemorrhagic fever, epidemic nephritis, nephropathia epidemica, Balkan hemorrhagic fever, Hantavirus, Hantavirus pulmonary syndrome, HPS, Seoul virus, end-stage renal disease, ESRD, Puumala virus, PUUV, Myodes glareolus, Dobrava virus, DOBV, Apodemus flavicollis, Saaremaa virus, SAAV, Apodemus agrarius, Sin Nombre virus, proteinuria, microhematuria, Hantavirus nephritis, acute abdomen, oliguria, pulmonary edema, thrombocytopenia, hyponatremia, hyperphosphatemia, hyperkalemia, acute tubular necrosis, hemorrhagic necrosis

Contributor Information and Disclosures

Author

Rajendra Bhimma, MB, ChB, Associate Professor of Pediatrics, Principal Specialist, Department of Pediatrics and Child Health, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, South Africa
Rajendra Bhimma, MB, ChB is a member of the following medical societies: American Association for the Advancement of Science, International Society of Nephrology, and South African Medical Association
Disclosure: Nothing to disclose.

Coauthor(s)

Vellore K Sairam, MBBS, Assistant Professor, Department of Nephrology, Sri Ramachandra Medical College and Research Institute, India
Disclosure: Nothing to disclose.

Luther Travis, MD, William W Glauser Professor of Pediatrics and Pediatric Nephrology, Department of Pediatrics, Divisions of Nephrology and Diabetes, University of Texas Medical Branch and Children's Hospital
Luther Travis, MD is a member of the following medical societies: Alpha Omega Alpha, American Federation for Medical Research, International Society of Nephrology, and Texas Pediatric Society
Disclosure: Nothing to disclose.

Medical Editor

Deogracias Pena, MD, Medical Director of Dialysis, Department of Pediatrics, Cook Children's Medical Center; Clinical Associate Professor, Texas Tech University School of Medicine
Deogracias Pena, MD is a member of the following medical societies: American Academy of Pediatrics, American Medical Association, and American Society of Pediatric Nephrology
Disclosure: Nothing to disclose.

Pharmacy Editor

Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine.com, Inc
Disclosure: Pfizer Inc Stock Investment from broker recommendation; Avanir Pharma Stock Investment from broker recommendation

Managing Editor

Frederick J Kaskel, MD, PhD, Director of the Division and Training Program in Pediatric Nephrology, Vice Chair, Department of Pediatrics, Montefiore Medical Center and Albert Einstein School of Medicine
Frederick J Kaskel, MD, PhD is a member of the following medical societies: Academy of Medical Royal Colleges, American Academy of Pediatrics, American Association for the Advancement of Science, American Heart Association, American Pediatric Society, American Physiological Society, American Society of Nephrology, American Society of Pediatric Nephrology, American Society of Transplantation, Eastern Society for Pediatric Research, Federation of American Societies for Experimental Biology, International Society of Nephrology, National Kidney Foundation, New York Academy of Sciences, Renal Physicians Association, Sigma Xi, and Society for Pediatric Research
Disclosure: Nothing to disclose.

CME Editor

Howard Trachtman, MD, Program Director, Pediatrics Research, Schneider Children's Hospital, Department of Pediatrics, Division of Nephrology, Professor, Albert Einstein College of Medicine
Howard Trachtman, MD is a member of the following medical societies: American Society of Hypertension, American Society of Nephrology, American Society of Pediatric Nephrology, and Society for Pediatric Research
Disclosure: Nothing to disclose.

Chief Editor

Craig B Langman, MD, The Isaac A Abt, MD, Professor of Kidney Diseases, Feinberg School of Medicine, Northwestern University; Division Head of Kidney Diseases, Children's Memorial Hospital, Chicago
Craig B Langman, MD is a member of the following medical societies: American Academy of Pediatrics, American Society of Nephrology, and International Society of Nephrology
Disclosure: Amgen Grant/research funds None; Abbott Honoraria Speaking and teaching; Altus Pharmaceuticals Grant/research funds None; Genzyme Grant/research funds None; Merck Grant/research funds None; NIH Grant/research funds None

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.